US Edition
Akeso Announces First Patient Enrollment in Phase III Trial of Ivonescimab for Pancreatic Cancer
- Akeso announced that the first patient was enrolled in a Phase III trial of ivonescimab for pancreatic cancer treatment.
- The trial investigates ivonescimab's combination with chemotherapy, potentially enhancing treatment options for patients with metastatic pancreatic cancer.
- This study is part of Akeso's strategy to meet unmet clinical needs in global oncology, focusing on pancreatic cancer treatment.
- Doctors hope that combining ivonescimab with ligufalimab will improve anti-tumor activity in patients.
74 Articles
74 Articles
Bennington Banner
Akeso Announces First Patient Enrollment in Phase III Trial of Ivonescimab for Pancreatic Cancer
HONG KONG, July 23, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the first patient has been enrolled in the pivotal/registration Phase III clinical trial (AK112-310/HARMONi-GI2) of ivonescimab, a first-in-class PD-1/VEGF bispecific antibody…
Immunotherapy Response May Be Influenced by Patient’s Own Autoantibodies
A landmark study headed by researchers at Yale School of Medicine and at Fred Hutchinson Cancer Center has revealed that autoantibodies (AAbs)—immune proteins traditionally associated with autoimmune disease—may profoundly influence how cancer patients respond to checkpoint immunotherapy (CPI). Results from the research, involving humans and mice, could represent a potential breakthrough in solving one of modern-day oncology’s most frustrating m…
Coverage Details
Bias Distribution
- 61% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
